Perspectives of improvement of the diagnosis of prostate cancer based on analysis of PCA3 gene expression


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Prostate cancer is the second leading cause of cancer death. The widespread introduction into the clinical practice of test for prostate specific antigen (PSA) led to an increase in the number of prostate biopsies performed. At the same time, a decrease in the threshold of age-specific PSA standards has resulted in an increase in the number of unnecessary biopsies. In this regard, a need has arisen for new prostate cancer biomarkers. PCA3 is a non-coding mRNA that is exclusively expressed by prostate cells. Currently, three generations of test diagnostic systems based on the quantitative analysis of the PCA3 mRNA in the urine or its cell sediment has already developed, and they differ in the type of material studied and the method for estimating the amount of PCA3 mRNA. Clinical studies of the developed test systems have shown that a high level of PCA3 expression in the patient’s urine correlates with the probability of detecting prostate cancer. PCA3 test has higher positive and negative predictive values than previously used PSA test. These data are repeatedly confirmed by studies conducted in different clinics. Thus, the introduction of the method of quantitative determination of PCA3 in clinical practice can significantly improve the efficiency of diagnosis of prostate cancer and reduce the number of unnecessary biopsies.

Full Text

Restricted Access

About the authors

A. N Toropovsky

LLC «TestGen»

Ph.D., clinical laboratory scientist, general director

A. G Nikitin

LLC «TestGen»

Ph.D., head of the Laboratory of Genetics

O. N Pavlova

LLC «TestGen»

Email: casiopeya13@maiI.ru
doctor of biological sciences, assistant professor, researcher

D. A Viktorov

LLC «TestGen»

Ph.D. in biology, head of research laboratory

References

  1. Сидоренков А.В., Говоров А.В., Пушкарь Д.Ю., Павлов К.А., Шкопоров А.Н., Хохлова Е.В., Корчагина А.А., Григорьев М.Э., Чехонин В.П. Российская тест-система РСА3: первые результаты. Экспериментальная и клиническая урология. 2014;2:36-43
  2. Babaian R.J., Mettlin C., Kane R., Murphy G.P., Lee F., Drago J.R., Chesley A. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography: findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1992;69(5):1195- 1200.
  3. Hodge K.K., McNeal J.E., Terris M.K., Stamey T.A., Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol. 1989;142:71-75.
  4. Павлов К.А., Шкопоров А.Н., Хохлова Е.В., Корчагина А.А., Сидоренков А.В., Григорьев М.Э., Пушкарь Д.Ю., Чехонин В.П. Разработка диагностической тест-системы для ранней неинвазивной диагностики рака простаты, основанной на количественной детекции мРНК гена PCA3 в осадке мочи методом ОТ-ПЦР в режиме реального времени. ВЕСТНИК РАМН. 2013;5:45-51
  5. Hammerer P., Huland H. Systemic sextant biopsies in 651 patients referred for prostate evaluation. J. Urol. 1994;151(1):99-102.
  6. Svetec D., McCabe K., Peretsman S., Klein E., Levin H., Optenberg S., Thompson I. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J. Urol. 1998;159(5):1606-1608.
  7. Сивков А.В., Ефремов Г.Д., Михайленко Д.С., Григорьева М.В. Комбинация маркеров ПСА-3 и TMPRSS2 в ранней диагностике рака предстательной железы (обзор литературы). Экспериментальная и клиническая урология. 2014;3:20-26
  8. Guichard G., Larre S., Gallina A., Lazar A., Faucon H., Chemama S., Allory Y., Patard J.J., Vordos D., Hoznek A., Yiou R., Salomon L., Abbou C.C., de la Taille A. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol. 2007;52:430-435
  9. Сидоренков А.В., Пушкарь Д.Ю. РСА3 - истинный онкомаркер рака предстательной железы (обзор литературы). Онкоурология. 2014;2:70-77
  10. Пешков М.Н. PСA3 - новый маркер диагностики неотрансформации в предстательной железе. Медицинский алфавит. Современная лаборатория. 2014;1-2:21-23
  11. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., Debruyne F.M., Ru N., Isaacs W.B. DD3: a new prostatespecific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59(23):5975-5979
  12. Павлов К.А., Корчагина А.А., Абдулина Ю.А., Суренков Д.Н., Зусьман Л.А., Даренков С.П., Григорьев М.Э., Чехонин В.П. РСА3 - перспективный биомаркер рака предстательной железы. Вестник Российского государственного медицинского университета. 2012;3:54-58
  13. Пушкарь Д.Ю., Говоров А.В. Маркеры рака предстательной железы. Экспериментальная и клиническая урология. 2011;2-3:19-21
  14. de Kok J.B., Verhaegh G.W., Roelofs R.W., Hessels D., Kiemeney L.A., Aalders T.W., Swinkels D.W., Schalken J.A. DD3 (PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62(9):2695-2698]
  15. Marks L.S., Fradet Y. et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007;69:532-535.
  16. Bradley L.A., Palomaki G.E., Gutman S. et al. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 2013;190(2):389-98. Doi: 10.1016/j. juro.2013.02.005. PMID: 23545099.
  17. Cui Y., Cao W., Li Q. et al. Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep 2016;6:25776. doi: 10.1038/srep25776. PMID: 27161545.
  18. Ramos C.G., Valdevenito R., Vergara I.et al. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Urol Oncol. 2013;31(8):1522-1526.
  19. Deras I.L., Aubin S.M., Blase A., Day J.R., Koo S., Partin A.W., Ellis W.J., Marks L.S., Fradet Y., Rittenhouse H., Groskopf J. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008 Apr;179(4):1587- 1592.
  20. Hessels D. Klein Gunnewiek J.M., van Oort I. et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44(1):8-15.
  21. Nakanishi H., Groskopf J., Fritsche H.A., Bhadkamkar V., Blase A., Kumar S.V., Davis J.W., Troncoso P., Rittenhouse H., Babaian R.J. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol 2008;179(5):1804-1809.
  22. Fradet Y., Saad F., Aprikian A., Dessureault J., Elhilali M., Trudel C., Masse B., Piche L., Chypre C. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64(2):311-315.
  23. Tinzl M., Marberger M., Horvath S., Chypre C. DD3 PCA3 RNA analysis in urine-- a new perspective for detecting prostate cancer. Eur Urol. 2004;46(2):182-186.
  24. Vlaeminck-Guillem V., Bandel M., Cottancin M. et al. Chronic prostatitis does not influence urinary PCA3 score. Prostate 2012;72(5):549-554.
  25. Тороповский А.Н., Никитин А.Г., Гордиев М.Г., Викторов Д.А., Мухаметханова Л.М., Павлова О.Н. Результаты испытания набора реагентов для выявления мРНК гена PCA3 и определения уровня его экспрессии методом двустадийной ОТ-ПЦР-РВ (ПРОСТА-ТЕСТ) для диагностики рака предстательной железы in vitro в клинической практике. Вестник медицинского института «РЕАВИЗ». 2018;1:126-136
  26. Hessels D., Schalken J.A. The use of PCA3 in the diagnosis of prostate cancer. Nat Rev Urol 2009;6(5):255-261.
  27. Durand X., Moutereau S., Xylinas E., de la Taille A. Progensa™ PCA3 test for prostate cancer. Expert Rev Mol Diagn. 2011;11(2):137-144.
  28. Wang T., Qu X., Jiang J. et al. Diagnostic significance of urinary long noncoding PCA3 RNA in prostate cancer. Oncotarget. 2017.
  29. Hendriks R. J., Dijkstra S., Jannink S. A. et al. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clin Chem Lab Med. 2016;54(3):483-492.
  30. Quek S.I., Wong O.M., Chen A. et al. Processing of voided urine for prostate cancer RNA biomarker analysis. Prostate. 2015;75(16):1886-1895.
  31. Shappell S.B. Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol. 2008 Winter; 10(1):44-69.
  32. Tomlins S.A., Bjartell A., Chinnaiyan A.M., Jenster G., Nam R.K., Rubin M.A., Schalken J.A. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56(2):275-286.
  33. Petrovics G., Liu A., Shaheduzzaman S. et al. Frequent overexpression of ETS-related gene-1 [ERG1] in prostate cancer transcriptome. Oncogene. 2005;24:3847-3852.
  34. Clark J., Merson S., Jhavar S., et. al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2007;26:2667-2673.
  35. Van Leenders G.J., Boormans J.L., Vissers C.J. et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Mod Pathol. 2011;24(8):1128-1138.
  36. Leyten G.H., Hessels D., Jannink S.A. et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014;65(3):534-542.
  37. Аполихин О.И., Сивков А.В., Ефремов Г.Д., и соавт. PCA3 и TMPRSS2-ERG в диагностике рака предстательной железы: первый опыт применения комбинации маркеров в России. Экспериментальная и клиническая урология. 2015;2:30-36
  38. Hessels D., Smit F.P., Verhaegh G.W., et al. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clinical Cancer Res. 2007; 13:5103- 5108.
  39. Lin D.W., Newcomb L.F., Brown E.C. et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the canary prostate active surveillance study. Clin Cancer Res. 2013;19:2442- 2450.
  40. Robert G., Jannink S., Smit F. et al. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate. 2013;73(2):113-120.
  41. Arlen P.M., Bianco F., Dahut W.L. et al. Prostate Specific Antigen Working Groupguidelines on prostate specific antigendoubling time. J. Urol. 2008;179(6):2181-2185.
  42. Hessels D., van Gils M.P., van Hooij O. et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010.; 70(1):10-16.
  43. Roobol M.J. Prostate cancer biomarkers to improve risk stratification: is our knowledge of prostate cancer sufficient to spare prostate biopsies safely. Eur Urol. 2011;60:223. doi: 10.1016/j.eururo.2011.04.006.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies